ライフサイエンスコーパス: copeptin

1 eased, as assessed by the cosecreted protein copeptin.

2 veral novel biomarkers - galectin-3, ST2 and copeptin.

3 lated copeptin than with arginine-stimulated copeptin.

4 receiver operating characteristic curves for copeptin (0.75) and NTproBNP (0.76) were similar.

5 eath or HF at 1 year (adjusted hazard ratio: copeptin, 1.71; MR-proADM, 1.96; MR-proANP, 2.20; all p

6 entified an increased risk of CV death or HF(copeptin: 13.2% vs. 5.0%, p < 0.001; MR-proADM: 15.8% vs

7 higher in samples with raised osmolality or copeptin (a surrogate marker for AVP).

8 s in humans show increased concentrations of copeptin, a surrogate marker of arginine vasopressin (AV

9 Copeptin, a surrogate marker of vasopressin, was elevate

10 ove the median of approximately 900 pmol/L), copeptin above the median (approximately 7 pmol/L) was a

11 We analyzed the association of copeptin, an established surrogate for AVP, with paramet

12 prospectively study the association between copeptin and 1-year mortality in patients with out-of-ho

13 [CI], 67.0 to 80.6) for arginine-stimulated copeptin and 95.6% (95% CI, 91.1 to 97.8) for hypertonic

14 We compared the prognostic value of copeptin and an established marker, N-terminal pro-B-typ

15 A negative copeptin and cTnI at baseline ruled out AMI for 58% of p

16 Both abnormal copeptin and cTnI were predictors of death at 180 days (

17 th T1D, hypoglycemia failed to increase both copeptin and glucagon.

18 -head comparison between arginine-stimulated copeptin and hypertonic saline-stimulated copeptin in th

19 nal prohormone of brain natriuretic peptide, copeptin, and high-sensitivity cardiac troponin I) remai

20 tivation-regulated chemokine, transthyretin, copeptin, and high-sensitivity troponin I) were selected

21 ion showed significant differences in SMD of copeptin, and the heterogeneity among studies was signif

22 cement causes serum elevations of NT-proBNP, copeptin as well as specific circulating miRNAs, indicat

23 For both admission and day 3 copeptin, association with 1-year mortality existed for

24 Arginine-stimulated copeptin at a value of 3.0 pmol per liter or less led to

25 With use of copeptin concentration as a surrogate measure of AVP con

26 ng fractional uric acid excretion and plasma copeptin concentration, may further improve the diagnost

27 A close correlation between copeptin concentrations and serum osmolality existed in

28 Furthermore, saline-induced changes in copeptin concentrations correlated with changes in AVP c

29 lasma arginine vasopressin (AVP), and plasma copeptin concentrations from 50 patients with hyponatrem

30 osmotic thresholds (type B); 44% had normal copeptin concentrations independent of osmolality (type

31 osmolality (type C), and 12% had suppressed copeptin concentrations independent of osmolality (type

32 Ten percent of patients had grossly elevated copeptin concentrations independent of serum osmolality

33 endent of serum osmolality (type A); 14% had copeptin concentrations that increased linearly with ris

34 ts was characterized by a linear decrease in copeptin concentrations with increasing serum osmolality

35 ocin precursor and suggests that the loss of copeptin contributes to 87STOP pathogenicity.

36 is suggests that early measurement of plasma copeptin could provide better prognostic information abo

37 N-terminal pro-BNP (NT-proBNP), copeptin (CT-proAVP), and miRNA expression profiles were

38 iagnostic accuracy according to prespecified copeptin cutoff values of 3.8 pmol per liter after 60 mi

39 Dapagliflozin treatment increased serum copeptin early (5.5 pmol/L [95% CI: 0.45-10.5]; P < 0.05

40 .1 to 97.8) for hypertonic saline-stimulated copeptin (estimated difference, -21.2 percentage points;

41 undetected by cTnI at 0 h were detected with copeptin >14 pmol/l in 10 (53%) of 19 patients.

42 y the initial cTnI alone were picked up with copeptin >14 pmol/l in 23 (72%) of 32 patients.

43 corresponding wild-type proteins from which copeptin had been deleted, leading to the following conc

44 Hypertonic saline-stimulated copeptin has been used to diagnose AVP deficiency with h

45 Arginine-stimulated copeptin has shown similar diagnostic accuracy but with

46 h or heart failure with both biomarkers (log copeptin [hazard ratio, 2.33], log NTproBNP [hazard rati

47 mia also increases circulating levels of AVP/copeptin in humans and this hormone stimulates glucagon

48 ed copeptin and hypertonic saline-stimulated copeptin in the diagnosis of AVP deficiency.

49 We investigated the release of cTns and copeptin in the first hours after experimental balloon-i

50 s provides an explanation for the absence of copeptin in the more stable oxytocin precursor and sugge

51 sistent argument for a role for glycosylated copeptin in vasopressin precursor folding in vivo, copep

52 -terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery d

53 During HYPER, plasma osmolality and copeptin increased (P < 0.05) and remained elevated duri

54 Copeptin is a stable arginine vasopressin precursor asso

55 Copeptin is secreted from the pituitary early in the cou

56 A positive association was found between the copeptin level and the presence of renal cysts (odds rat

57 assess the prognostic significance of plasma copeptin level on functional outcome and mortality in pa

58 ncrease at 180 minutes), while the mean (SD) copeptin level was 4.9 (3.8) pmol/L and slightly decreas

59 In multivariable analyses, the copeptin level was associated inversely with eGFR (beta=

60 An elevated plasma copeptin level was associated with an increased risk of

61 le showing no correlation with the change in copeptin level.

62 e goal of this study was to demonstrate that copeptin levels <14 pmol/L allow ruling out acute myocar

63 Copeptin levels and a contemporary sensitive cTnI (99 th

64 Secondary endpoints included changes in copeptin levels and solute free water clearance.

65 Copeptin levels did not change significantly.

66 Copeptin levels did not significantly change.

67 Serum NT-proBNP and copeptin levels exceeded the upper reference limit after

68 acroalbuminuria, and perhaps, elevated serum copeptin levels in affected adults.

69 The 529 women and 481 men had median copeptin levels of 3.0 and 5.2 pmol/L, respectively (P<0

70 rdized mean difference (SMD) was that plasma copeptin levels were found to be significantly higher in

71 Copeptin levels were log-transformed.

72 The association of plasma oxytocin or copeptin levels with plasma sodium level at 180 minutes

73 Plasma oxytocin, copeptin (marker of vasopressin), and sodium levels were

74 Copeptin may have a supplementary role in ruling out myo

75 Copeptin may predict adverse outcome, especially in thos

76 In the 980 patients, copeptin (measured at days 3 to 5) was elevated in patie

77 ic performance of C-terminal provasopressin (copeptin), midregional pro-adrenomedullin (MR-proADM), a

78 in in vasopressin precursor folding in vivo, copeptin most probably assisting refolding by facilitati

79 Copeptin, MR-proADM, and MR-proANP are complementary pro

80 Copeptin, MR-proADM, and MR-proANP are emerging biomarke

81 We measured copeptin, MR-proADM, and MR-proANP concentrations in 4,4

82 Novel biomarkers (Copeptin, MR-proADM, and MR-proANP) and common signs and

83 With logistic regression analysis, copeptin (odds ratio, 4.14, P<0.0005) and NTproBNP (odds

84 hypertonic saline stimulation together with copeptin (or AVP) measurement.

85 curve (0.84) than for NTproBNP (P<0.013) or copeptin (P<0.003) alone, respectively.

86 SCD) was estimated by plasma renin (PRC) and copeptin (PCC) concentrations.

87 activity is inversely correlated with fetal copeptin production, a surrogate marker of vasopressin,

88 a was associated with acute oxytocin but not copeptin release.

89 copeptin were mutually adjusted, only day 3 copeptin remained associated with 1-year mortality in a

90 ed by 2 independent cardiologists blinded to copeptin results.

91 utation deletes the precursor's glycosylated copeptin segment, which has been considered unnecessary

92 higher in samples with raised osmolality and copeptin (surrogate marker for AVP).

93 diagnosed with hypertonic saline-stimulated copeptin than with arginine-stimulated copeptin.

94 of AVP neurons in vivo increased circulating copeptin (the C-terminal segment of the AVP precursor pe

95 Copeptin, the C-terminal part of provasopressin, has eme

96 Copeptin, the C-terminal part of the vasopressin prohorm

97 Day 3 copeptin was superior to admission copeptin: this could permit identification of out-of-hos

98 Adding copeptin to cTnI allowed safe rule out of AMI with a neg

99 Copeptin was analyzed by a sandwich immunoluminometric a

100 Copeptin was assessed at admission and day 3.

101 Day 3 copeptin was associated with 1-year mortality in a dose-

102 fter multivariate analysis, higher admission copeptin was associated with 1-year mortality with a thr

103 Plasma copeptin was highest on admission (n=132, P<0.001, day 1

104 Day 3 copeptin was superior to admission copeptin: this could

105 High levels of copeptin were associated with 1-year mortality independe

106 When admission and day 3 copeptin were mutually adjusted, only day 3 copeptin rem

107 However, the positive association of copeptin with poor prognosis after stroke was consistent

108 ssion analysis to explore the association of copeptin with renal function parameters as well as kidne